The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review
Authors:
- 21 November 2024
- journal article
- review article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 117, 118010
Abstract
No abstract availableKeywords
This publication has 146 references indexed in Scilit:
- Development of antibody‐drug conjugates in cancer: Overview and prospectsCancer Communications, 2023
- Pivotal Biology, Chemistry, Biochemistry, and Biophysical Concepts of Biologics and Biosimilars2020
- Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapyJournal of Cellular Physiology, 2019
- Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successesJournal of Cellular Physiology, 2018
- Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapyJournal of Cellular Physiology, 2018
- Antibody–Drug Conjugates: An Emerging Concept in Cancer TherapyAngewandte Chemie International Edition, 2014
- The Antibody Drug Absorption Following Subcutaneous or Intramuscular Administration and Its Mathematical Description by Coupling Physiologically Based Absorption Process with the Conventional Compartment Pharmacokinetic ModelThe Journal of Clinical Pharmacology, 2013
- A Traceless Vascular‐Targeting Antibody–Drug Conjugate for Cancer TherapyAngewandte Chemie International Edition, 2011
- Evaluation of a Non-Arrhenius Model for Therapeutic Monoclonal Antibody AggregationJournal of Pharmaceutical Sciences, 2011
- Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemiasCancer Chemotherapy and Pharmacology, 2009